Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value
$3.09−0.03 (-0.96%)
Close on Nov 13, 2026Market cap $769.99MP/E –Yield –
Ardelyx total assets
Total assets on the balance sheet at the end of each period.
Ardelyx's total assets was $575.89M at Jun 30, 2026. For fiscal 2025 it was $501.60M, up 15.1% from the year before. Over ten years it grew 15.7% a year on average. The highest annual figure on record is $501.60M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.60M | +15.1% |
| FY2024 | Dec 31, 2024 | $435.75M | +46.4% |
| FY2023 | Dec 31, 2023 | $297.58M | +56.6% |
| FY2022 | Dec 31, 2022 | $190.07M | +26.8% |
| FY2021 | Dec 31, 2021 | $149.91M | -25.6% |
| FY2020 | Dec 31, 2020 | $201.56M | -22.4% |
| FY2019 | Dec 31, 2019 | $259.78M | +41.7% |
| FY2018 | Dec 31, 2018 | $183.33M | +16.1% |
| FY2017 | Dec 31, 2017 | $157.90M | -25.9% |
| FY2016 | Dec 31, 2016 | $213.13M | +82.2% |
| FY2015 | Dec 31, 2015 | $116.95M | +3.1% |
| FY2014 | Dec 31, 2014 | $113.41M | +164.3% |
| FY2013 | Dec 31, 2013 | $42.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $575.89M | +23.4% |
| Q1 FY2026 | Mar 31, 2026 | $504.51M | +23.0% |
| Q4 FY2025 | Dec 31, 2025 | $501.60M | +15.1% |
| Q3 FY2025 | Sep 30, 2025 | $486.17M | +32.2% |
| Q2 FY2025 | Jun 30, 2025 | $466.77M | +35.9% |
| Q1 FY2025 | Mar 31, 2025 | $410.19M | +19.8% |
| Q4 FY2024 | Dec 31, 2024 | $435.75M | +46.4% |
| Q3 FY2024 | Sep 30, 2024 | $367.86M | +27.1% |
| Q2 FY2024 | Jun 30, 2024 | $343.49M | +62.6% |
| Q1 FY2024 | Mar 31, 2024 | $342.38M | +57.8% |
| Q4 FY2023 | Dec 31, 2023 | $297.58M | +56.6% |
| Q3 FY2023 | Sep 30, 2023 | $289.38M | +100.0% |
| Q2 FY2023 | Jun 30, 2023 | $211.20M | +60.5% |
| Q1 FY2023 | Mar 31, 2023 | $217.02M | +67.7% |
| Q4 FY2022 | Dec 31, 2022 | $190.07M | +26.8% |
| Q3 FY2022 | Sep 30, 2022 | $144.67M | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $131.61M | -35.8% |
| Q1 FY2022 | Mar 31, 2022 | $129.41M | -38.5% |
| Q4 FY2021 | Dec 31, 2021 | $149.91M | -25.6% |
| Q3 FY2021 | Sep 30, 2021 | $170.85M | -14.0% |
| Q2 FY2021 | Jun 30, 2021 | $204.98M | -5.7% |
| Q1 FY2021 | Mar 31, 2021 | $210.29M | -10.6% |
| Q4 FY2020 | Dec 31, 2020 | $201.56M | -22.4% |
| Q3 FY2020 | Sep 30, 2020 | $198.56M | +66.3% |
| Q2 FY2020 | Jun 30, 2020 | $217.34M | +57.5% |
| Q1 FY2020 | Mar 31, 2020 | $235.32M | +41.6% |
| Q4 FY2019 | Dec 31, 2019 | $259.78M | +41.7% |
| Q3 FY2019 | Sep 30, 2019 | $119.41M | -42.2% |
| Q2 FY2019 | Jun 30, 2019 | $137.98M | -39.6% |
| Q1 FY2019 | Mar 31, 2019 | $166.14M | +16.3% |
| Q4 FY2018 | Dec 31, 2018 | $183.33M | +16.1% |
| Q3 FY2018 | Sep 30, 2018 | $206.67M | +44.4% |
| Q2 FY2018 | Jun 30, 2018 | $228.54M | +39.2% |
| Q1 FY2018 | Mar 31, 2018 | $142.84M | -23.9% |
| Q4 FY2017 | Dec 31, 2017 | $157.90M | -25.9% |
| Q3 FY2017 | Sep 30, 2017 | $143.11M | -40.7% |
| Q2 FY2017 | Jun 30, 2017 | $164.12M | – |
| Q1 FY2017 | Mar 31, 2017 | $187.77M | – |
| Q4 FY2016 | Dec 31, 2016 | $213.13M | – |
| Q3 FY2016 | Sep 30, 2016 | $241.32M | – |
See a number that looks wrong?